

Drugs and Therapeutics (D & T) Committee
Meeting Results
January 13, 2022

Drug Name	Review Type	Committee Recommendation	Preferred Status – Final Determination
Qelbree	New Drug Appeal	Preferred with PA	Non-Preferred
Lybalvi	New Drug Initial Review	Preferred with PA	Non-Preferred
Invega Hafyera	New Drug Initial Review	Preferred with PA	Non-Preferred
Myfembree	New Drug Initial Review	Preferred with PA	Preferred with PA
Qulipta	New Drug Initial Review	Preferred with PA	Preferred with PA

Anti-Asthmatics-Adrenergic Agents
Class Review Results

ADVAIR DISKUS	PREFERRED		
ADVAIR HFA	PREFERRED		
GENERIC ADVAIR			NON-PREFERRED
WIXELA			NON-PREFERRED
GENERIC WIXELA			NON-PREFERRED
AIRDUO DIGIHALER	PREFERRED		
AIRDUO RESPICLIK	PREFERRED		
GENERIC AIRDUO			NON-PREFERRED
ANORA ELLIPTA	PREFERRED		
BEVESPI			NON-PREFERRED
BREO ELLIPTA			NON-PREFERRED
BREZTRI AERO			NON-PREFERRED
COMBIVENT			NON-PREFERRED
DULERA	PREFERRED		
IPRATROPIUM/ALBUTEROL	PREFERRED		
STIOLTO			NON-PREFERRED
SYMBICORT	PREFERRED		
GENERIC SYMBICORT			NON-PREFERRED
TRELEGY ELLIPTA			NON-PREFERRED

Anti-Asthmatics-Combination Anticholinergic Agents
Class Review Results

ATROVENT HFA	PREFERRED		
INCRUSE ELLIPTA	PREFERRED		
IPRATROPIUM SOL 0.02%	PREFERRED		
LONHALA MAGN			NON-PREFERRED
SPIRIVA AER 1.25MCG	PREFERRED		
SPIRIVA HANDIHALER	PREFERRED		
SPIRIVA 2.5MCG	PREFERRED		
TUDORZA			NON-PREFERRED
YUPELRI SOL			NON-PREFERRED